Tarassoff P - Search Results

1

A phase I clinical, plasma, and cellular pharmacology study of gemcitabine.

Abbruzzese JL, Grunewald R, Weeks EA, Gravel D, Adams T, Nowak B, Mineishi S, Tarassoff P, Satterlee W, Raber MN, et al. Abbruzzese JL, et al. Among authors: tarassoff p. J Clin Oncol. 1991 Mar;9(3):491-8. doi: 10.1200/JCO.1991.9.3.491. J Clin Oncol. 1991. PMID: 1999720 Clinical Trial.

2

Phase II study of gemcitabine in advanced colorectal adenocarcinoma.

Moore DF Jr, Pazdur R, Daugherty K, Tarassoff P, Abbruzzese JL. Moore DF Jr, et al. Among authors: tarassoff p. Invest New Drugs. 1992 Nov;10(4):323-5. doi: 10.1007/BF00944189. Invest New Drugs. 1992. PMID: 1487408 Clinical Trial.

3

Gemcitabine in leukemia: a phase I clinical, plasma, and cellular pharmacology study.

Grunewald R, Kantarjian H, Du M, Faucher K, Tarassoff P, Plunkett W. Grunewald R, et al. Among authors: tarassoff p. J Clin Oncol. 1992 Mar;10(3):406-13. doi: 10.1200/JCO.1992.10.3.406. J Clin Oncol. 1992. PMID: 1740680 Clinical Trial.

4

Saturation of 2',2'-difluorodeoxycytidine 5'-triphosphate accumulation by mononuclear cells during a phase I trial of gemcitabine.

Grunewald R, Abbruzzese JL, Tarassoff P, Plunkett W. Grunewald R, et al. Among authors: tarassoff p. Cancer Chemother Pharmacol. 1991;27(4):258-62. doi: 10.1007/BF00685109. Cancer Chemother Pharmacol. 1991. PMID: 1998982 Clinical Trial.

5

Pharmacologically directed design of the dose rate and schedule of 2',2'-difluorodeoxycytidine (Gemcitabine) administration in leukemia.

Grunewald R, Kantarjian H, Keating MJ, Abbruzzese J, Tarassoff P, Plunkett W. Grunewald R, et al. Among authors: tarassoff p. Cancer Res. 1990 Nov 1;50(21):6823-6. Cancer Res. 1990. PMID: 2208147

6

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas.

Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, Tarassoff PG. Casper ES, et al. Among authors: tarassoff pg. Invest New Drugs. 1994;12(1):29-34. doi: 10.1007/BF00873232. Invest New Drugs. 1994. PMID: 7960602 Clinical Trial.

7

Phase I clinical trial of gemcitabine given as an intravenous bolus on 5 consecutive days.

O'Rourke TJ, Brown TD, Havlin K, Kuhn JG, Craig JB, Burris HA, Satterlee WG, Tarassoff PG, Von Hoff DD. O'Rourke TJ, et al. Among authors: tarassoff pg. Eur J Cancer. 1994;30A(3):417-8. doi: 10.1016/0959-8049(94)90276-3. Eur J Cancer. 1994. PMID: 8204374 Clinical Trial. No abstract available.

8

Phase II trial of gemcitabine in patients with advanced gastric cancer.

Christman K, Kelsen D, Saltz L, Tarassoff PG. Christman K, et al. Among authors: tarassoff pg. Cancer. 1994 Jan 1;73(1):5-7. doi: 10.1002/1097-0142(19940101)73:1<5::aid-cncr2820730103>3.0.co;2-#. Cancer. 1994. PMID: 8275437 Clinical Trial.

9

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer.

Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA 3rd, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD. Rothenberg ML, et al. Among authors: tarassoff pg. Ann Oncol. 1996 Apr;7(4):347-53. doi: 10.1093/oxfordjournals.annonc.a010600. Ann Oncol. 1996. PMID: 8805925 Free article. Clinical Trial.

10

Maximum-tolerated dose defined for single-agent gemcitabine: a phase I dose-escalation study in chemotherapy-naive patients with advanced non-small-cell lung cancer.

Fossella FV, Lippman SM, Shin DM, Tarassoff P, Calayag-Jung M, Perez-Soler R, Lee JS, Murphy WK, Glisson B, Rivera E, Hong WK. Fossella FV, et al. Among authors: tarassoff p. J Clin Oncol. 1997 Jan;15(1):310-6. doi: 10.1200/JCO.1997.15.1.310. J Clin Oncol. 1997. PMID: 8996158 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

19 results

Search Page